{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:32:51Z","timestamp":1790389971718,"version":"4.1.0"},"reference-count":112,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T00:00:00Z","timestamp":1596931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020","doi-asserted-by":"publisher","award":["101003551"],"award-info":[{"award-number":["101003551"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The pandemic evolution of SARS-CoV-2 infection is forcing the scientific community to unprecedented efforts to explore all possible approaches against COVID-19. In this context, targeting virus entry is a promising antiviral strategy for controlling viral infections. The main strategies pursued to inhibit the viral entry are considering both the virus and the host factors involved in the process. Primarily, direct-acting antivirals rely on inhibition of the interaction between ACE2 and the receptor binding domain (RBD) of the Spike (S) protein or targeting the more conserved heptad repeats (HRs), involved in the membrane fusion process. The inhibition of host TMPRSS2 and cathepsins B\/L may represent a complementary strategy to be investigated. In this review, we discuss the development entry inhibitors targeting the S protein, as well as the most promising host targeting strategies involving TMPRSS2 and CatB\/L, which have been exploited so far against CoVs and other related viruses.<\/jats:p>","DOI":"10.3390\/ijms21165707","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T05:07:23Z","timestamp":1597036043000},"page":"5707","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells"],"prefix":"10.3390","volume":"21","author":[{"given":"Rolando","family":"Cannalire","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Napoli \u201cFederico II\u201d, via D. Montesano 49, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Stefanelli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Napoli \u201cFederico II\u201d, via D. Montesano 49, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cerchia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Napoli \u201cFederico II\u201d, via D. Montesano 49, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6830-2695","authenticated-orcid":false,"given":"Andrea R.","family":"Beccari","sequence":"additional","affiliation":[{"name":"Domp\u00e9 Farmaceutici SpA, via Campo di Pile, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveva","family":"Pelliccia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Napoli \u201cFederico II\u201d, via D. Montesano 49, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Summa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Napoli \u201cFederico II\u201d, via D. Montesano 49, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,9]]},"reference":[{"key":"ref_1","unstructured":"WHO (2019). Ten Threats to Global Health in 2019, WHO. Available online: https:\/\/www.who.int\/emergencies\/ten-threats-to-global-health-in-2019."},{"key":"ref_2","unstructured":"WHO (2020). Prioritizing Diseases for Research and Development in Emergency Contexts, WHO. Available online: Https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-anddevelopment-In-emergency-contexts."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","unstructured":"(2020, June 08). Rolling Updates on Coronavirus Disease (COVID-19). Available online: Https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/jtm\/tax026","article-title":"2020 Hubei Lockdowns","volume":"24","author":"Riddle","year":"2020","journal-title":"J. Travel Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0140-6736(20)30690-5","article-title":"COVID-19 in Europe: The Italian lesson","volume":"395","author":"Saglietto","year":"2020","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","article-title":"COVID-19 and Italy: What next?","volume":"395","author":"Remuzzi","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cpt.1862","article-title":"Off-Label Therapies for COVID-19-Are We All In This Together?","volume":"108","author":"Alpern","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Goldman, J.D., Lye, D.C.B., Hui, D.S., Marks, K.M., Bruno, R., Montejano, R., Spinner, C.D., Galli, M., Ahn, M.-Y., and Nahass, R.G. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2015301"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., Hohmann, E., Chu, H.Y., Luetkemeyer, A., and Kline, S. (2020). Remdesivir for the Treatment of Covid-19\u2014Preliminary Report. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2007764"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J. Adv. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3201\/eid2607.200282","article-title":"High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2","volume":"26","author":"Sanche","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis","volume":"Volume 1282","author":"Fehr","year":"2015","journal-title":"Coronaviruses: Methods and Protocols"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","article-title":"The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex","volume":"77","author":"Bosch","year":"2003","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.aivir.2016.08.001","article-title":"Viral and Cellular mRNA Translation in Coronavirus-Infected Cells","volume":"Volume 96","author":"Nakagawa","year":"2016","journal-title":"Advances in Virus Research"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.chom.2012.04.011","article-title":"Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology","volume":"11","author":"Zhao","year":"2012","journal-title":"Cell Host Microbe"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","article-title":"Reviews Of Anti-infective Agents: Maraviroc: The First of a New Class of Antiretroviral Agents","volume":"47","author":"MacArthur","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/molecules16010221","article-title":"Targeting cell entry of enveloped viruses as an antiviral strategy","volume":"16","author":"Teissier","year":"2011","journal-title":"Molecules"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature16988","article-title":"Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer","volume":"531","author":"Walls","year":"2016","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15092","article-title":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains","volume":"8","author":"Yuan","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1073\/pnas.1708727114","article-title":"Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion","volume":"114","author":"Walls","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structural biology: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Song, W., Gui, M., Wang, X., and Xiang, Y. (2018). Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLOS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007236"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1016\/j.jmb.2020.04.009","article-title":"Phylogenetic analysis and structural modeling of SARS-CoV-2 Spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop","volume":"432","author":"Jaimes","year":"2020","journal-title":"J. Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.virol.2005.02.022","article-title":"Central ions and lateral asparagine\/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein","volume":"335","author":"Duquerroy","year":"2005","journal-title":"Virology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"ref_43","unstructured":"Zhang, G., Pomplun, S., Loftis, A.R., Loas, A., and Pentelute, B.L. (2020). The first-in-class peptide binder to the SARS-CoV-2 spike protein. bioRxiv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.0400576101","article-title":"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides","volume":"101","author":"Bosch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_47","first-page":"1","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","article-title":"Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors","volume":"363","author":"Liu","year":"2004","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0092-8674(00)80066-5","article-title":"Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket","volume":"99","author":"Eckert","year":"1999","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1073\/pnas.93.5.2186","article-title":"Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion","volume":"93","author":"Lambert","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/13543776.2014.987752","article-title":"Peptide fusion inhibitors targeting the HIV-1 gp41: A patent review (2009\u20132014)","volume":"25","author":"Zhang","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP1369","article-title":"Current peptide HIV type-1 fusion inhibitors","volume":"20","author":"Pang","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e00288-18","DOI":"10.1128\/JVI.00288-17","article-title":"A Lipopeptide HIV-1\/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity","volume":"91","author":"Chong","year":"2017","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.1021\/acs.jmedchem.8b00890","article-title":"De Novo Design of \u03b1-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00635-20","DOI":"10.1128\/JVI.00635-20","article-title":"Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity","volume":"94","author":"Zhu","year":"2020","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Musarrat, F., Chouljenko, V., Dahal, A., Nabi, R., Chouljenko, T., Jois, S.D., and Kousoulas, K.G. (2020). The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J. Med. Virol.","DOI":"10.1101\/2020.04.24.060376"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J. Virol."},{"key":"ref_59","first-page":"1","article-title":"TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection","volume":"93","author":"Okamura","year":"2019","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1128\/JVI.01542-10","article-title":"Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2","volume":"84","author":"Matsuyama","year":"2010","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.biocel.2007.11.013","article-title":"Type II transmembrane serine proteases in development and disease","volume":"40","author":"Szabo","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1099\/vir.0.80955-0","article-title":"Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein","volume":"86","author":"Fukushi","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.molmed.2009.05.003","article-title":"Type II transmembrane serine proteases in cancer and viral infections","volume":"15","author":"Choi","year":"2009","journal-title":"Trends Mol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1042\/BJ20041066","article-title":"The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells","volume":"388","author":"Wilson","year":"2005","journal-title":"Biochem. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1128\/JVI.00140-10","article-title":"Cleavage of Influenza Virus Hemagglutinin by Airway Proteases TMPRSS2 and HAT Differs in Subcellular Localization and Susceptibility to Protease Inhibitors","volume":"84","author":"Freuer","year":"2010","journal-title":"J. Virol."},{"key":"ref_68","unstructured":"(2020, June 08). TMPRSS2\u2014An overview | ScienceDirect Topics. Available online: https:\/\/www.sciencedirect.com\/topics\/biochemistry-genetics-and-molecular-biology\/tmprss2."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antiviral Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome Coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Yamamoto, M., Kiso, M., Sakai-Tagawa, Y., Iwatsuki-Horimoto, K., Imai, M., Takeda, M., Kinoshita, N., Ohmagari, N., Gohda, J., and Semba, K. (2020). The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses, 12.","DOI":"10.3390\/v12060629"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/0306-3623(95)00072-0","article-title":"Mechanisms of hyperkalemia caused by nafamostat mesilate","volume":"26","author":"Muto","year":"1995","journal-title":"Gen. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis","volume":"4","author":"Lucas","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1021\/jm100183e","article-title":"Identification of the first low-molecular-weight inhibitors of matriptase-2","volume":"53","author":"Sisay","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1021\/jm960668h","article-title":"Synthesis and structure-activity relationships of potent thrombin inhibitors: Piperazides of 3-amidinophenylalanine","volume":"40","author":"Prasa","year":"1997","journal-title":"J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1016\/j.bmcl.2011.06.033","article-title":"Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT","volume":"21","author":"Sielaff","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1042\/BJ20130101","article-title":"Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation","volume":"452","author":"Meyer","year":"2013","journal-title":"Biochem. J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e202000786","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7635","DOI":"10.1038\/s41598-020-64368-8","article-title":"Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression","volume":"10","author":"Shen","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2017.11.012","article-title":"Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry","volume":"517","author":"Shirato","year":"2018","journal-title":"Virology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e01387-16","DOI":"10.1128\/JVI.01387-16","article-title":"Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry","volume":"91","author":"Shirato","year":"2017","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1172\/JCI42918","article-title":"Specialized roles for cysteine cathepsins in health and disease","volume":"120","author":"Reiser","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/13543776.12.3.419","article-title":"Recent developments of cathepsin inhibitors and their selectivity","volume":"12","author":"Kang","year":"2002","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/13543776.2011.553800","article-title":"Cathepsin S inhibitors: 2004\u20132010","volume":"21","author":"Wiener","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1367-5931(02)00345-9","article-title":"Recent advances in the synthesis, design and selection of cysteine protease inhibitors","volume":"6","author":"Hernandez","year":"2002","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Dana, D., and Pathak, S.K. (2020). A review of small molecule inhibitors and functional probes of human cathepsin L.. Molecules, 25.","DOI":"10.3390\/molecules25030698"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.antiviral.2013.09.028","article-title":"Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research","volume":"100","author":"Simmons","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.virol.2006.01.007","article-title":"A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L.","volume":"346","author":"Pager","year":"2006","journal-title":"Virology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/13543776.2017.1272572","article-title":"Cathepsin B and L inhibitors: A patent review (2010 - present)","volume":"27","author":"Li","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/j.1460-2075.1991.tb07771.x","article-title":"The refined 2.15 A X-ray crystal structure of human liver cathepsin B: The structural basis for its specificity","volume":"10","author":"Musil","year":"1991","journal-title":"EMBO J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ab.2004.09.012","article-title":"Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: Assays with human cathepsin B","volume":"335","author":"Cotrin","year":"2004","journal-title":"Anal. Biochem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jsb.2010.09.007","article-title":"Structural basis for reversible and irreversible inhibition of human cathepsin L by their respective dipeptidyl glyoxal and diazomethylketone inhibitors","volume":"173","author":"Shenoy","year":"2011","journal-title":"J. Struct. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/bi00429a058","article-title":"Crystal Structure of a Papain\u2013E-64 Complex","volume":"28","author":"Varughese","year":"1989","journal-title":"Biochemistry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1042\/bj2010189","article-title":"L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins, B, H and L.","volume":"201","author":"Barrett","year":"1982","journal-title":"Biochem. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(99)01107-2","article-title":"Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo","volume":"458","author":"Katunuma","year":"1999","journal-title":"FEBS Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1006\/bbrc.1999.1830","article-title":"Inhibition Mechanism of Cathepsin L-Specific Inhibitors Based on the Crystal Structure of Papain\u2013CLIK148 Complex","volume":"266","author":"Tsuge","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.188.4.725","article-title":"Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection","volume":"188","author":"Engel","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3762\/bjoc.9.3","article-title":"Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target","volume":"9","author":"Choy","year":"2013","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1128\/AAC.49.12.5160-5161.2005","article-title":"A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi","volume":"49","author":"Barr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1371\/journal.pmed.0020210","article-title":"Designing drugs for parasitic diseases of the developing world","volume":"2","author":"McKerrow","year":"2005","journal-title":"PLoS Med."},{"key":"ref_102","first-page":"1343","article-title":"In vitro evaluation of the disposition of a novel cysteine protease inhibitor","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1371\/journal.pmed.0040014","article-title":"Schistosomiasis mansoni: Novel chemotherapy using a cysteine protease inhibitor","volume":"4","author":"Abdulla","year":"2007","journal-title":"PLoS Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1021\/bi027308i","article-title":"Specificity Determinants of Human Cathepsin S Revealed by Crystal Structures of Complexes","volume":"42","author":"Pauly","year":"2003","journal-title":"Biochemistry"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nsb0297-105","article-title":"Crystal structure of human cathepsin K complexed with a potent inhibitor","volume":"4","author":"McGrath","year":"1997","journal-title":"Nat. Struct. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0022-2836(02)00780-5","article-title":"The Crystal Structure of Human Cathepsin F and Its Implications for the Development of Novel Immunomodulators","volume":"322","author":"Somoza","year":"2002","journal-title":"J. Mol. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cmdc.201000109","article-title":"Novel peptidyl aryl vinyl sulfones as highly potent and selective inhibitors of cathepsins L and B","volume":"5","author":"Mendieta","year":"2010","journal-title":"Chem. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/095632020401500102","article-title":"Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and \u03b2-D-N4-hydroxycytidine","volume":"15","author":"Barnard","year":"2004","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3940(98)00266-3","article-title":"Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia","volume":"247","author":"Li","year":"1998","journal-title":"Neurosci. Lett."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuropharm.2015.05.040","article-title":"Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy","volume":"97","author":"Kharatmal","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1016\/j.bmcl.2008.04.065","article-title":"Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype","volume":"18","author":"Myers","year":"2008","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1021\/ci100114e","article-title":"Molecular Docking of Cathepsin L Inhibitors in the Binding Site of Papain","volume":"50","author":"Beavers","year":"2010","journal-title":"J. Chem. Inf. Model."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/16\/5707\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:58:27Z","timestamp":1760176707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/16\/5707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,9]]},"references-count":112,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["ijms21165707"],"URL":"https:\/\/doi.org\/10.3390\/ijms21165707","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,9]]}}}